… E-mail: l.tweehuysen@maartenskliniek.nl. Submitted for publication June 17, 2016; …
Tweehuysen had full access to all of the data in the study and takes responsibility for the integrity of …

Introduction Although bDMARDs are effective in the treatment of RA, they are associated with
dose-dependent side effects, patient burden, and high costs. Recently, many studies have …

Objective To evaluate drug survival, effectiveness, pharmacokinetics, immunogenicity, and
safety in daily practice after transitioning treatment from original reference infliximab (…

… E-mail: l.tweehuysen@maartenskliniek.nl. Submitted for publication November 14, 2017; …
Tweehuysen had full access to all of the data in the study and takes responsibility for the …

Background The extracellular domains of cytokine receptors are released during inflammation,
but little is known about the shedding of Toll-like receptors (TLR) and whether they can …

Objective. To investigate predictors of flare in rheumatoid arthritis (RA) patients with low disease
activity (LDA) and to evaluate the effect of flare on 12-month clinical outcomes. Methods. …

Background In blinded trials, transitioning from an innovator to a biosimilar has shown to be
equivalent to maintenance on innovator biologic treatment in rheumatic diseases. However, …

Objectives Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid
arthritis (RA). The aim of this study was to investigate the predictive value of serum …

Background After adalimumab treatment failure, tumour necrosis factor inhibition (TNFi) and
non-TNFi biological disease-modifying anti-rheumatic drugs (bDMARDs) are equally viable …

About 60% of RA patients don’t achieve good response with biological disease-modifying
anti-rheumatic drugs bDMARD treatment (including TNF inhibitors, TNFi’s). Previously, a link …